Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2020-10-27 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
2020年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled "2020 年第三季度报告" which translates to "2020 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes for the third quarter of 2020. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content includes unaudited financial statements for the quarter ending September 30, 2020, with comparative data from previous periods. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. There is no indication that this is an announcement or a certification document, so it is not classified as RPA or RNS. Therefore, the correct classification is Interim / Quarterly Report (IR). 9M 2020
2020-10-27 Chinese
关于参加北京辖区上市公司投资者集体接待日的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an investor collective reception day event, including details about the event's date, time, and participation method. It mentions communication topics such as governance, strategy, operations, financing plans, and sustainability, but does not contain any financial statements, detailed financial data, or report content. The document is short (542 characters) and serves as a notice to investors about an upcoming event rather than a report or transcript. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-09-01 Chinese
2020年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2020 年半年度报告摘要' which translates to '2020 Semi-Annual Report Summary'. It contains detailed financial data for the first half of 2020, including net profit, R&D expenses, assets, and liabilities. It discusses the company's operating results, financial condition, risks, and future plans. The document length is over 7,000 characters and includes substantive financial data and analysis for a period shorter than a full fiscal year. It is not merely an announcement or a certification but a comprehensive interim report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-08-27 Chinese
第一届监事会第十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. regarding the approval of the company's 2020 semi-annual report and a special report on the use of raised funds. It references the 2020 semi-annual report and a special report but does not contain the actual financial statements or detailed financial data itself. The document is short (1342 characters) and states that the detailed reports are disclosed on the Shanghai Stock Exchange website. This fits the pattern of an announcement about the approval and disclosure of reports rather than the reports themselves. Therefore, it should be classified as a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR) or Annual Report (10-K).
2020-08-27 Chinese
2020年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2020 年半年度报告' which translates to '2020 Semi-Annual Report'. It covers the period from January 1, 2020 to June 30, 2020, indicating it is a report for a period shorter than a full fiscal year. The content includes detailed financial data such as net profit, revenue, assets, and liabilities, as well as extensive business and operational information. The length of the document is about 15,000 characters, which is substantial and consistent with a full interim/quarterly report rather than a brief announcement or summary. The document explicitly states it is a half-year report and includes financial statements and management discussion. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-08-27 Chinese
2020年半年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised by the company during the first half of 2020. It includes specifics about the amount raised, the timing of fund receipt, the balance of funds, usage status, regulatory compliance, and related approvals. The document references regulatory guidelines on fundraising management and includes financial figures related to fundraising but does not present comprehensive financial statements or overall company financial performance. The document is titled as a "专项报告" (special report) on fundraising usage for the half-year period ending June 30, 2020. This type of document is a specialized report on capital raising and fund usage, which aligns with the category of Capital/Financing Update (CAP). It is not an annual or interim financial report, nor an announcement of a report publication. Therefore, the correct classification is CAP with high confidence.
2020-08-27 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.